# Qiyu Biotechnology (Shanghai)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qiyu-biotechnology-shanghai

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.qurebio.com
- Total disclosed funding: $45M
- Latest round: Series C (Jun 5, 2025)
- Investors on record: 11

## About

Based in Shanghai, China and established in 2017, Hunan Qiyu Biotechnology Co., Ltd., trading as Qiyu Biotechnology (Shanghai), operates as a biopharmaceutical company which focuses on developing new drugs of cancer and autoimmune diseases, especially antibody. The company has cooperated with BRL Medicine, Bio Map, Hengrui Pharmaceuticals, and Precious Benchmark. In January 2026, Qiyu Biotechnology (Shanghai) raised a venture funding from Beijia Investment Management.
The company has established several innovative platforms include phage display platform, hybridoma antibody humanization platform, single domain antibody platform and antibody engineering. Among them, the hybridoma antibody humanization platform is able to overcome immune tolerance and has completed several projects with antigens from multiple transmembrane regions, the phage display platform is a synthetic human library platform for bispecific antibody screening of common light chain libraries.
The company's revenue is generated by providing drugs of cancer and autoimmune diseases.

## Funding rounds

- Series C, Jun 5, 2025, $14M — Efung Capital
- Series B, Dec 23, 2021, $31M — Oriza Holdings, BOCOM International Asset Management, Tririver Capital, Zhuhai Longmen Capital Management, Zhuhai Zijing Hongxin Investment Management, Zhangjiang Torch Investment, Guoshun Investment
- Series A, Apr 10, 2020 — Shenzhen Capital Real Estate Fund
- Series A, Dec 3, 2018 — Watson Capital, Jundu Capital

## Investors

- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Series A
- Jundu Capital (https://capitalatlas.ai/funds/jundu-capital) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- BOCOM International Asset Management (https://capitalatlas.ai/funds/bocom-international-asset-management) — Series B
- Tririver Capital (https://capitalatlas.ai/funds/tririver-capital) — Series B
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series B
- Zhuhai Zijing Hongxin Investment Management — Series B
- Zhangjiang Torch Investment (https://capitalatlas.ai/funds/zhangjiang-torch-investment) — Series B
- Guoshun Investment (https://capitalatlas.ai/funds/guoshun-investment) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series C